Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effects

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 9868-9874

  Moynihan, Humphrey A ^a   Derrick, Ian ^a   Broadbear, Jillian H ^c,e   Greedy, Benjamin M ^d   Aceto, Mario D ^b   Harris, Louis S ^b   Purington, Lauren C S ^c   Thomas, Mark P ^d   Woods, James H ^c   Traynor, John R ^c   Husbands, Stephen M ^d   Lewis, John W ^d  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d University of Bath   (United Kingdom)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 O (TERT BUTYLDIMETHYLSILYL) N CYCLOPROPYLMETHYL 7,8 DIHYDRO 14 BETA [3' (METHOXYCARBONYL)PROPENOYLOXY]NORMORPHINONE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; BREMAZOCINE; BUPRENORPHINE; FUMAROYLAMINO 4,5 EPOXYMORPHINAN; MORPHINAN DERIVATIVE; MORPHINE; MORPHINONE; MU OPIATE RECEPTOR ANTAGONIST; N CYCLOPROPYLMETHYL 6,14 ENDOETHANO 7 ALPHA (METHOXYFUMAROYLAMINO)TETRAHYDRONORORIPAVINE; N CYCLOPROPYLMETHYL 6,14 ENDOETHANO 7 ALPHA (METHOXYFUMAROYLAMINOMETHYL)TETRAHYDRONORORIPAVINE; N CYCLOPROPYLMETHYL 7,8 DIHYDRO 14 BETA [3' (METHOXYCARBONYL)PROPENAMIDO]NORMORPHINONE; N CYCLOPROPYLMETHYL 7,8 DIHYDRO 14 BETA [3' (METHOXYCARBONYL)PROPENOYLOXY]NORMORPHINONE; NALOXONE; OPIATE; OPIATE AGONIST; OPIATE RECEPTOR; ORIPAVINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; MOUSE; NONHUMAN;

ANALGESICS, OPIOID; ANIMALS; BRAIN; HAPLORHINI; MICE; MOLECULAR STRUCTURE; MORPHINE DERIVATIVES; NARCOTIC ANTAGONISTS; NOCICEPTION; PAIN MEASUREMENT; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE;

EID: 84870033137     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301096s     Document Type: Article

References (25)

1. Takemori, A. E.; Larson, D. L.; Portoghese, P. S. The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone Eur. J. Pharmacol. 1981, 70, 445-451
2. 3H]β-funaltrexamine covalent binding in the cloned rat μ opioid receptor J. Biol. Chem. 1996, 271, 21422-21429
3. Rennison, D.; Moynihan, H.; Traynor, J. R.; Lewis, J. W.; Husbands, S. M. Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the C14-amino to aryl ring linker chain J. Med. Chem. 2006, 49, 6104-6110
4. Rennison, D.; Neal, A. P.; Cami-Kobeci, G.; Aceto, M. D.; Bermejo, F. M.; Lewis, J. W.; Husbands, S. M. Cinnamoyl derivatives of 7α-aminomethyl-6, 14-endoethanotetrahydrothebaine and 7α-aminomethyl-6,14- endoethanotetrahydrooripavine and related opioid ligands J. Med. Chem. 2007, 50, 5176-5182
5. Nieland, N. P. R.; Moynihan, H.; Carrington, S.; Broadbear, J.; Woods, J. H.; Traynor, J. R.; Husbands, S. M.; Lewis, J. W. Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones J. Med. Chem. 2006, 49, 5333-5338
6. Derrick, I.; Husbands, S. M.; Broadbear, J.; Traynor, J. R.; Woods, J. H.; Lewis, J. W. Cinnamoyl derivatives of 7α-amino and 7α-aminomethyl- N -cyclopropylmethyl-6,14-endo-etheno- tetrahydronororipavines are high potency opioid antagonists Helv. Chim. Acta 2000, 83, 3122-3130
7. Broadbear, J. H.; Sumpter, T. L.; Burke, T. F.; Husbands, S. M.; Lewis, J. W.; Woods, J. H.; Traynor, J. R. Methcinnamox is a potent, long-lasting and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, β-FNA and β-chlornaltrexamine J. Pharmacol. Exp. Ther. 2000, 294, 933-940
8. Derrick, I.; Moynihan, H. A.; Broadbear, J.; Woods, J. H.; Lewis, J. W. 6 N -Cinnamoyl-β-naltrexamine and its p -nitro derivative. High efficacy κ-opioid agonists with weak antagonist actions Bioorg. Med. Chem. Lett. 1996, 6, 167-172
9. Derrick, I.; Lewis, J. W.; Moynihan, H. A.; Broadbear, J.; Woods, J. H. Potential irreversible ligands for opioid receptors. Cinnamoyl derivatives of β-naltrexamine J. Pharm. Pharmacol. 1996, 48, 192-196
10. Zernig, G.; Burke, T.; Lewis, J. W.; Woods, J. H. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioural assays J. Pharmacol. Exp. Ther. 1996, 279, 23-31
11. Derrick, I.; Lewis, J. W.; Woods, J. H.; Broadbear, J.; Plumer, H. Cinnamoylamidomethyloripavines: preliminary in-vivo evaluation of potential new affinity ligands for opioid receptors Analgesia 1995, 1, 386-389
12. Cowan, A.; Lewis, J. W., Eds. Buprenorphine; Wiley-Liss: New York, 1995; 326 pp.
13. Walker, E. A.; Comer, S. D. Experimental Utility and Clinical Potential of Irreversible Opioid Antagonists. In Opiate Receptors and Antagonists; Dean, R.; Bilsky, E. J.; Negus, S. S., Eds.; Humana Press: New York, 2009; pp p153-174.
14. Toll, L.; Berzetei-Gurske, I. P.; Polgar, W. E.; Brandt, S. R.; Adapa, I. D.; Rodriguez, L.; Schwartz, R. W.; Haggart, D.; O'Brien, A.; White, A.; Kennedy, J. M.; Craymer, K.; Farrington, L.; Auh, J. S. Standard binding and functional assays related to (NIDA) Medications Development Division testing for potential cocaine and narcotic treatment programs NIDA Res. Monogr. 1998, 178, 440-466
15. Pelton, J. T.; Kazmierski, W.; Gulya, K.; Yamamura, H. I.; Hruby, V. J. Design and synthesis of conformationally constrained somatostatin analogs with high potency and specificity for.mu. opioid receptors J. Med. Chem. 1986, 29, 2370-2375
16. Portoghese, P. S.; Lipkowski, A. W.; Takemori, A. E. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists Life Sci. 1987, 40, 1287-1292
17. Aceto, M. D.; Bowmen, E. R.; May, E. L.; Woods, J. H.; Smith, C. B.; Medzihradsky, F.; Jacobson, A. E. Very long-acting narcotic antagonists: the 14β-p-substituted cinnamoylaminomorphinones and their partial mu agonist codeinone relatives Arzneim. Forsch./Drug Res. 1989, 39, 570-575
18. Derrick, I. Cinnamoylamino and Methoxyfumaroylamino Derivatives of Epoxymorphinans. Potential Irreversible Ligands for Opioid Receptors. Ph.D. Thesis, University of Bristol, U.K., 1996.
19. Rothman, R. B.; Long, J. B.; Holaday, J. W.; Bykov, V.; De Costa, B. R.; Kim, C.-H.; Jacobson, A. E.; Rice, K. C. A study of the interaction of the alkylating agent, NIH10236, with opioid receptors in vitro and in vivo Neuropharmacology 1989, 28, 1349-1356
20. Sayre, L. M.; Larson, D. L.; Fries, D. S. Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels J. Med. Chem. 1983, 26, 1229-1235
21. Piggot, N. G.; Derrick, I.; Husbands, S. M.; Lewis, J. W. Molecular modeling of cinnamoyl derivatives in two epoxymorphinan series. Correlation with pharmacological profiles Analgesia 1995, 1, 647-650
22. Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Mathiesen, J. M.; Sunahara, R. K.; Pardo, L.; Weis, W. I.; Kobilka, B. K.; Granier, S. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist Nature 2012, 485, 321-327
23. Moynihan, H.; Jales, A. R.; Greedy, B. M.; Broadbear, J. H.; Purington, L.; Traynor, J. R.; Woods, J. H.; Lewis, J. W.; Husbands, S. M. 14β- O -Cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity J. Med. Chem. 2009, 52, 1553-1557
24. Bodor, N.; Buchwald, P. Soft drug design: general principles and recent applications Med. Res. Rev. 2000, 20, 58-101
25. Nagase, H.; Abe, A.; Portoghese, P. S. The facility of formation of a delta-6 bond in dihydromorphinone and related opiates J. Org. Chem. 1989, 54, 4120-4125